Search

New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.

… Thursday, May 11, 2023 Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins. KRAS , for example, normally acts as an on/off switch for cellular proliferation, but mutations to the gene — common in lung cancer, colorectal cancer

Ingo Mellinghoff is optimistic about the future of brain cancer treatments as the new Chair of MSK’s Department of Neurology.

… Thursday, March 11, 2021 Summary Neuro-oncologist Ingo Mellinghoff first became intrigued by scientific questions regarding brain tumors while working in the lab of physician-scientist Charles Sawyers before both came to MSK. Now, Dr. Mellinghoff leads MSK’s Department of Neurology as it deploys innovative

Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

… Wednesday, December 14, 2011 Summary Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma. Stand Up To Cancer (SU2C) has appointed five Memorial Sloan Kettering scientists to its new “Dream

In case you missed it, here’s a recap of Monday’s highlights from the American Society of Clinical Oncology annual meeting.

… Tuesday, June 7, 2016 Summary The challenges of using immunotherapy to treat older patients, an update to an important melanoma clinical trial, and a visit from Vice President Joe Biden were among Monday’s highlights at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. With

On Thursday, June 18th at 6:00 p.m. E.T. with an encore at 9:00 p.m., MSK will stream a special performance highlighting poignant and humorous perspectives On Cancer and Coronavirus, featuring works from its writing program, Visible Ink.

… Thursday, June 18, 2020 On Thursday, June 18 th at 6:00 p.m. E.T. with an encore at 9:00 p.m. , Memorial Sloan Kettering Cancer Center (MSK) will stream a special performance on visibleink.vimeo.mskcc.org , highlighting poignant and humorous perspectives On Cancer and Coronavirus, featuring works from

An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.

… Friday, January 30, 2015 Summary An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study. Epigenetics — the study of biochemical changes that influence a cell’s genetic programming

The MD Anderson Cancer Center presented its annual award to Dr. Scheinberg in recognition of his pioneering work in developing chemotherapeutic agents for leukemia and other cancers.

… Wednesday, June 6, 2012 Summary The MD Anderson Cancer Center presented its annual award to Dr. Scheinberg in recognition of his pioneering work in developing chemotherapeutic agents for leukemia and other cancers. David A. Scheinberg has received the 2012 Emil J. Freireich Award. The award, which is

At Memorial Sloan Kettering Cancer Center’s 43rd annual event recognizing graduates and award winners, honorees were welcomed back to an in-person event.

… Friday, May 20, 2022 GSK dean and graduates in their caps and gowns GSK Dean Michael Overholtzer (center) poses with GSK graduates (from left) Kevin Boehm, Corina Amor Vegas, Jacob Boyer, Amy Shyu, Hsuan-An Chen, and Rui Gao. Line of people in caps and gowns The platform party lines up at the beginning

Memorial Sloan Kettering Cancer Center (MSK) today announced that the New York State Department of Health has issued approval for a new molecular assay, Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS).  MSK-ACCESS was developed within the Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO) and the test has been clinically validated and implemented by members of MSK’s Molecular Diagnostics Service.

… Tuesday, June 11, 2019 Memorial Sloan Kettering Cancer Center (MSK) announced that the New York State Department of Health has issued an approval for a new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS). MSK-ACCESS was developed within the Marie-Josée and

Memorial Sloan Kettering Cancer Center (MSK) today announced that Rémy Evard has joined as its new Chief Digital Officer and Head of Technology.

… Thursday, January 13, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced that Rémy Evard has joined as its new Chief Digital Officer and Head of Technology. In this role, Evard will be responsible for the overall design and execution of the organization’s digital strategy. Evard joins